Insight, China's Pharmaceutical Industry

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

AstraGenomics and Kactus announced a strategic collaboration agreement to accelerate development and commercialization of nucleic...

Company Drug

Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations

Fineline Cube Mar 5, 2026

Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that the U.S. Food and Drug Administration...

Company Drug

Novo Nordisk’s CagriSema Fails Non‑Inferiority Test Against Lilly’s Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss

Fineline Cube Mar 5, 2026

Novo Nordisk A/S (NYSE: NVO) announced that its Phase III REDEFINE 4 study (NCT06131437) failed...

Company

Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff

Fineline Cube Mar 5, 2026

Bayer AG (ETR: BAYN) released its 2025 financial results, recording EUR 45.6 billion (USD 52.84 billion) in group...

Company

Gilead Foundation Commits $12 Million to Community Health Worker HIV Prevention Initiative – 33 Organizations Across 15 U.S. Jurisdictions

Fineline Cube Mar 5, 2026

The Gilead Foundation announced a USD 12 million investment in 33 community‑based organizations spanning 14 states and...

Company Drug

Eli Lilly’s Eloralintide Wins CDE Approval for Phase III Trials in China – Weekly Amylin Agonist Targets Weight Management Market

Fineline Cube Mar 5, 2026

Eli Lilly and Company (NYSE: LLY) announced that China’s Center for Drug Evaluation (CDE) under...

Company Drug

Pyrotech Therapeutics’ PTT-936 Wins NMPA Approval – Novel ALPK1 Agonist Targets Bladder Cancer

Fineline Cube Mar 5, 2026

Pyrotech (Beijing) Biotechnology Co., Ltd. (“Pyrotech Therapeutics”) announced that its internally developed small‑molecule innate immune...

Company Drug

Konruns Pharma’s KC1036 Wins NMPA Approval – Dual‑Target VEGFR2/AXL Inhibitor Enters IO Combination Trials

Fineline Cube Mar 5, 2026

Beijing Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced that China’s National Medical Products Administration (NMPA) has...

Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026

Rallybio Corporation (NASDAQ: RLYB) and Candid Therapeutics, Inc. announced a definitive merger agreement whereby Rallybio will...

Company Drug

Sichuan Biokin’s CD33 ADC BL-M11D1 Wins NMPA Approval – Expands into Myelodysplastic Syndromes

Fineline Cube Mar 5, 2026

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China’s National Medical Products Administration (NMPA) has...

Company Drug

CMS’s CMS-D008 Wins NMPA Approval – INHBE siRNA Targets Fat‑Selective Weight Loss

Fineline Cube Mar 5, 2026

China Medical System Holdings Limited (CMS, HKG: 0867) announced clinical study approval from China’s National Medical...

Medical Device

Sanyou Medical’s 3D‑Printed SWINGO-3D Lumbar Cage Wins FDA 510(K) – Advances Spinal Fusion Technology

Fineline Cube Mar 5, 2026

Sanyou Medical (SHA: 688085) announced that its French subsidiary Implanet has received FDA 510(K) clearance for...

Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026

Edding Genor Group Holdings Limited (HKG: 6998) announced a supplemental agreement and termination agreement with Napeptide...

Company Drug

Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label

Fineline Cube Mar 4, 2026

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that Xuanyuening (bireociclib), a Category 1 CDK2/4/6 inhibitor developed...

Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the completion of a financing round raising RMB 1.277 billion...

Company Drug

Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter

Fineline Cube Mar 4, 2026

Bio-Thera Solutions Ltd (SHA: 688177) announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA)...

Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026

Star Sports Medicine Co., Ltd., a China‑based sports medical device manufacturer, submitted a prospectus to...

Company Drug

Kexing Biopharma’s GB19 Wins NMPA Approval for Cutaneous Lupus – BDCA2‑Targeted Therapy Expands Autoimmune Pipeline

Fineline Cube Mar 4, 2026

Kexing Biopharm Co., Ltd. (SHA: 688136) announced clinical trial approval from China’s National Medical Products Administration...

Company Drug

J&J’s Nipocalimab Wins FDA Fast Track for Lupus – FcRn Blocker Targets Autoantibody Diseases

Fineline Cube Mar 4, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that its investigational drug nipocalimab has received Fast Track...

Company Deals

Leman Biotech Raises RMB 200M Series A+ – Advances Ultra‑Low‑Dose Metabolically Armored CAR‑T

Fineline Cube Mar 4, 2026

Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly...

Insight, China's Pharmaceutical Industry

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data

RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations

Novo Nordisk’s CagriSema Fails Non‑Inferiority Test Against Lilly’s Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss

Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff

Gilead Foundation Commits $12 Million to Community Health Worker HIV Prevention Initiative – 33 Organizations Across 15 U.S. Jurisdictions

Eli Lilly’s Eloralintide Wins CDE Approval for Phase III Trials in China – Weekly Amylin Agonist Targets Weight Management Market

Pyrotech Therapeutics’ PTT-936 Wins NMPA Approval – Novel ALPK1 Agonist Targets Bladder Cancer

Konruns Pharma’s KC1036 Wins NMPA Approval – Dual‑Target VEGFR2/AXL Inhibitor Enters IO Combination Trials

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Sichuan Biokin’s CD33 ADC BL-M11D1 Wins NMPA Approval – Expands into Myelodysplastic Syndromes

CMS’s CMS-D008 Wins NMPA Approval – INHBE siRNA Targets Fat‑Selective Weight Loss

Sanyou Medical’s 3D‑Printed SWINGO-3D Lumbar Cage Wins FDA 510(K) – Advances Spinal Fusion Technology

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Kexing Biopharma’s GB19 Wins NMPA Approval for Cutaneous Lupus – BDCA2‑Targeted Therapy Expands Autoimmune Pipeline

J&J’s Nipocalimab Wins FDA Fast Track for Lupus – FcRn Blocker Targets Autoantibody Diseases

Leman Biotech Raises RMB 200M Series A+ – Advances Ultra‑Low‑Dose Metabolically Armored CAR‑T

You Missed

AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data

RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma

Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo

AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease